News

March 03, 2009
ImmunoGen, Inc. Announces Webcast of Presentation at the Barclays Capital Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 3, 2009-- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Barclays Capital Global Healthcare Conference will be webcast live. The presentation is scheduled to begin at 4:45 p.m. ET on March 10, 2009, and will be given at the Loews Miami Beach Hotel in Florida. The presentation will provide an update on ImmunoGen.

The webcast can be accessed through the Investor Information section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until March 17, 2009.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and the naked antibody AVE1642 is in clinical trials through the Company’s collaboration with sanofi-aventis. The most advanced TAP compound, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company’s collaboration with Genentech. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.

Source: ImmunoGen, Inc.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?